Back to search results
NCT07468123

Atrial Fibrillation Risk Estimation With Single-lead Handheld Electrocardiograms

Enrolling by Invitation
NAAges 18–90InterventionalDiagnostic
Massachusetts General Hospital
~200 participants
Updated 2026-03-12 on ClinicalTrials.gov
What's tested:1L ECG screeningPatch monitor

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
New AF diagnosis (%)
Measured over 1 year
+2 more outcomes measured

Conditions

Atrial Fibrillation (AF)

Explore related trials

Atrial Fibrillation

NCT07468123

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mass General Brigham

    Boston, Massachusettsno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Men and women aged 50-90 who are new or established patients in an MGH primary care or ambulatory cardiology practice
Willing to provide consent to participate in the study to access data from electronic health records (EHR)
At least 1 12-lead ECG obtained within 5 years prior to study start date for AF risk estimation
Have access to a smart phone or tablet to use with the AliveCor KardiaMobile 1L ECG device

Exclusion

History of atrial fibrillation or atrial flutter as documented in the patient's current electronic health record medical problem list or self-reported diagnosis
Implanted cardiac devices (pacemakers, implantable cardiac defibrillators, or cardiac resynchronization therapy, and implantable loop recorders)
History of allergy to adhesive

What this trial measures

  • New AF diagnosis (%)1 year

    Rate of new AF diagnosis

  • Acceptability and usefulness0

    Survey-based acceptability and usefulness of 1L ECG screening process

  • AI-based AF risk correlation0

    Correlation between 12-lead ECG-based AF risk and 1L ECG-based AF risk using AI model